150 related articles for article (PubMed ID: 25388166)
1. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer.
Cristóbal I; Rincón R; Manso R; Caramés C; Zazo S; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Clin Cancer Res; 2015 Jan; 21(2):347-56. PubMed ID: 25388166
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.
Cristóbal I; Caramés C; Rincón R; Manso R; Madoz-Gúrpide J; Torrejón B; González-Alonso P; Rojo F; García-Foncillas J
Oncotarget; 2017 Jun; 8(25):40169-40180. PubMed ID: 27517624
[TBL] [Abstract][Full Text] [Related]
3. Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation.
Cristóbal I; Rincón R; Manso R; Madoz-Gúrpide J; Caramés C; del Puerto-Nevado L; Rojo F; García-Foncillas J
Biochim Biophys Acta; 2014 Sep; 1842(9):1823-9. PubMed ID: 24997451
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer.
Zeng ZL; Luo HY; Yang J; Wu WJ; Chen DL; Huang P; Xu RH
Clin Cancer Res; 2014 Feb; 20(4):1042-52. PubMed ID: 24277452
[TBL] [Abstract][Full Text] [Related]
5. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Tabernero J; Garcia-Carbonero R; Cassidy J; Sobrero A; Van Cutsem E; Köhne CH; Tejpar S; Gladkov O; Davidenko I; Salazar R; Vladimirova L; Cheporov S; Burdaeva O; Rivera F; Samuel L; Bulavina I; Potter V; Chang YL; Lokker NA; O'Dwyer PJ
Clin Cancer Res; 2013 May; 19(9):2541-50. PubMed ID: 23532888
[TBL] [Abstract][Full Text] [Related]
7. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.
Rincón R; Cristóbal I; Zazo S; Arpí O; Menéndez S; Manso R; Lluch A; Eroles P; Rovira A; Albanell J; García-Foncillas J; Madoz-Gúrpide J; Rojo F
Oncotarget; 2015 Feb; 6(6):4299-314. PubMed ID: 25726524
[TBL] [Abstract][Full Text] [Related]
8. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC).
Berretta M; Zanet E; Nasti G; Lleshi A; Frustaci S; Fiorica F; Bearz A; Talamini R; Lestuzzi C; Lazzarini R; Fisichella R; Cannizzaro R; Iaffaioli RV; Berretta S; Tirelli U
Arch Gerontol Geriatr; 2012; 55(2):271-5. PubMed ID: 21937127
[TBL] [Abstract][Full Text] [Related]
10. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
[TBL] [Abstract][Full Text] [Related]
11. Platinum-sensitivity in metastatic colorectal cancer: towards a definition.
Chibaudel B; Tournigand C; Bonnetain F; Maindrault-Goebel F; Lledo G; André T; Larsen AK; Bengrine-Lefevre L; Louvet C; de Gramont A
Eur J Cancer; 2013 Dec; 49(18):3813-20. PubMed ID: 24011937
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Nöpel-Dünnebacke S; Schulmann K; Reinacher-Schick A; Porschen R; Schmiegel W; Tannapfel A; Graeven U
Z Gastroenterol; 2014 Dec; 52(12):1394-401. PubMed ID: 25474278
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Baraniskin A; Munding J; Schulmann K; Meier D; Porschen R; Arkenau HT; Graeven U; Schmiegel W; Tannapfel A; Reinacher-Schick A
Clin Colorectal Cancer; 2011 Mar; 10(1):24-9. PubMed ID: 21609932
[TBL] [Abstract][Full Text] [Related]
14. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy.
Klaver YL; Simkens LH; Lemmens VE; Koopman M; Teerenstra S; Bleichrodt RP; de Hingh IH; Punt CJ
Eur J Surg Oncol; 2012 Jul; 38(7):617-23. PubMed ID: 22572106
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.
Torrejón B; Cristóbal I; Caramés C; Prieto-Potín I; Chamizo C; Santos A; Sanz-Alvarez M; Serna-Blasco R; Luque M; Madoz-Gúrpide J; Rojo F; García-Foncillas J
World J Surg; 2018 Nov; 42(11):3771-3778. PubMed ID: 29796729
[TBL] [Abstract][Full Text] [Related]
17. Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery.
Shitara K; Matsuo K; Kondo C; Takahari D; Ura T; Inaba Y; Yamaura H; Sato Y; Kato M; Kanemitsu Y; Komori K; Ishiguro S; Sano T; Shimizu Y; Muro K
Oncology; 2011; 81(3-4):167-74. PubMed ID: 22057124
[TBL] [Abstract][Full Text] [Related]
18. PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.
Velmurugan BK; Lee CH; Chiang SL; Hua CH; Chen MC; Lin SH; Yeh KT; Ko YC
J Cell Physiol; 2018 Feb; 233(2):1300-1311. PubMed ID: 28516459
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer.
Cristóbal I; Manso R; Rincón R; Caramés C; Zazo S; Del Pulgar TG; Cebrián A; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Br J Cancer; 2014 Aug; 111(4):756-62. PubMed ID: 25003662
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience.
Cvetanovic A; Vrbic S; Filipovic S; Pejcic I; Milenkovic D; Milenkovic N; Zivkovic N
J BUON; 2013; 18(3):641-6. PubMed ID: 24065477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
